3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
48
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Urinary Bladder Neoplasms
11
Cholangiocarcinoma
11
Breast Neoplasms
10
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Doxorubicin
4
pembrolizumab
3
Radiotherapy
3
Radiation
3
Biopsy
3
pazopanib
2
palbociclib
2
abemaciclib
2
Immunoglobulin G
2
Ifosfamide
2
toripalimab
1
talimogene laherparepvec
1
silmitasertib
1
selinexor
1
ribociclib
1
peposertib
1
mirdametinib
1
liposomal doxorubicin
1
eribulin
1
durvalumab
1
cemiplimab
1
X-Rays
1
Vincristine
1
Temozolomide
1
Surgical Procedures, Operative
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
durvalumab
×
90 days
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled